1. DR KANHU CHARAN PATRO
M.D, D.N.B[RT], MBA, FICRO, FAROI, PDCR,
SEPTEMBER 2023 ISSUE/90th VOLUME
4. H. VON DER MAASE/JCO/2023 16th AUG 2023/BLADDER
Metastatic urinary bladder GC VS
Patients with stage IV -TCC and no prior systemic chemotherapy were randomized to
GC (gemcitabine 1,000 mg/m2 days 1, 8, and 15; cisplatin 70 mg/m2 day 2) or standard
MVAC every 28 days for a maximum of six cycles.
1. More GC patients completed six cycles of therapy, with fewer
dose adjustments. The toxic death rate was 1% on the GC arm
and 3% on the MVAC arm.
2. More GC than MVAC patients had grade 3/4 anemia (27% v
18%, respectively) and thrombocytopenia (57% v 21%,
3. Overall survival was similar on both arms (hazards ratio [HR],
1.04; 95% confidence interval [CI], 0.82 to 1.32; P = .75),
4. As were time to progressive disease (HR, 1.05; 95% CI, 0.85 to
1.30), time to treatment failure (HR, 0.89; 95% CI, 0.72 to 1.10),
and response rate (GC, 49%; MVAC, 46%).
5. MATTHEW T. BALLO/JNO/2023 17th AUG 2023/BRAIN
TUMOR TREATING FIELDS THERAPY GLIOBLASTOMA
Association of Tumor Treating Fields
(TTFields) therapy with survival
in newly diagnosed glioblastoma:
a systematic review
6. TJ WHELA/NEJM/2023 18th AUG 2023/BREAST
CAN WE OMIT RADIOTHERAPY AFTER BCS IN LUMINL VARIANT?
Breast cancer groups include - Group 1 (luminal A).
This group includes tumors that are ER positive and
PR positive, but negative for HER2
19. 31st AUGUST 2023/STEREO
RADIOTHERAPY IN HEAD AND NECK PARAGANGLIOMA
PRACTICAL RADIOTHERAPY PLANNING
The tumour is contoured as GTV and expanded by a small margin (3–5 mm) to form a
PTV based on department setup errors. 45 Gy in 25 fractions are prescribed, usually
delivered by IMRT or VMAT like other head and neck cancers. Stereotactic
radiotherapy (12–15 Gy) has also been used
1. These are very slow-growing tumours arising
in the neuroendocrine paraganglial cells.
2. They can present with local symptoms,
cranial nerve palsies or as incidental
3. They are usually, but not always, benign.
Common sites include the carotid
bifurcation (carotid body tumours), jugular
bulb or vagus.
4. The risks of surgery include bleeding and
nerve damage and are higher with larger
tumours. EBRT is an option for symptomatic,
progressive disease if the risks are thought
to be lower than those of surgery.
5. Ten-year local control rates are 95 percent
but with no randomized comparison to
24. 5th SEP 2023/TOXICITY
HALO SIGN AND REVERSE HOLO SIGN
ONCOLOGIC IMAGING A MULTIDISCIPLINARYAPPROACH
The reversed halo sign, also known as
the atoll sign, on chest CT is defined
as central ground-glass opacity
surrounded by denser consolidation of
crescentic shape (forming more than
three-fourths of a circle) or complete
ring. The consolidation should be at
least 2 mm in thickness
The halo sign has been pathophysiologically
characterized as a discrete nodule of
angioinvasive aspergillosis with infarction
and coagulative necrosis surrounded by
alveolar hemorrhage. IPA is considered to be
the most common cause of angioinvasive
fungal infection in severely
25. 6th SEP 2023/TOXICITY
FUNGAL PNEUMONIA IN CANCER PATIENTS
1. Sudden onset
3. Cough, usually nonproductive
4. Pleuritic chest pain or dull
5. Progressive dyspnea (shortness of
breath) leading to respiratory failure
1. Temperature elevation
4. Respiratory distress
6. Signs of pulmonary consolidation
7. Pleural rub
26. 7th SEP 2023/TOXICITY
BLEOMYCIN INDUCED PULMONARY TOXICTY
1. A 49-year-old man with Hodgkin’s lymphoma
developed increasing shortness of breath after
completion of the first cycle of chemotherapy
(ABVD) that progressed after the second cycle.
2. The lung injury seen following bleomycin
comprises an interstitial oedema with an influx of
inflammatory and immune cells.
3. This may lead to the development of pulmonary
fibrosis, characterized by enhanced production and
deposition of collagen and other matrix
1. Bronchoscopy did not show any organisms.
Bleomycin was discontinued and the patient was
treated with steroids with clinical resolution of
shortness of breath.
2. Chest CT scan 4 years after completion of
chemotherapy shows that some of the acute
changes that were seen in resolved, although
nonreversible peripheral bleomycin-induced
pulmonary fibrosis remained (arrows).
ONCOLOGIC IMAGING A MULTIDISCIPLINARYAPPROACH
34. 15th SEP 2023/PUBLIC
SEXUAL LIFE DURING CANCER TREATMENT
1. Cancer is not contagious; you can have it.
2. Your intimacy with your partner gives
confidence to your partner.
3. Do not force or put pressure your partner
4. During chemotherapy it is allowed but
use barrier method as some
chemo/immuno drugs secreted in body
5. During radiotherapy you can have it but
if radiation is around genital part, please
6. After surgery period you can have but
wait till your partner becomes healthy.
7. During radioactive treatment and
investigation avoid for few days as per
8. Never hesitate to ask your doctor